Nissen SE, Lincoff M, Wolski K, et al. - In statin-treated patients at high cardiovascular risk with raised triglyceride levels and low levels of high-density lipoprotein cholesterol treated with ω-3 fatty acids, researchers examined if achieved levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are linked with cardiovascular outcomes. They conducted a secondary analysis of a randomized clinical trial examining a carboxylic acid formulation of ω-3 fatty acids. Measurement of plasma levels of EPA and DHA was done 12 months following randomization in 10,382 patients. Findings revealed no correlation between achieved or change in level of either ω-3 fatty acid and major adverse cardiovascular events. Hence, no support was gained for the concept that achieving higher EPA plasma levels through pharmacological means lowers adverse cardiovascular outcomes, nor was there correlation of higher DHA levels linked with harm.